Table 1.
Demographic characteristics and metadata of the ADNI rsfMRI dataset (N = 155)
| CN (N = 34) | SMC (N = 24) | EMCI (N = 43) | LMCI (N = 31) | AD (N = 23) | P‐value | |
|---|---|---|---|---|---|---|
| Baseline age (years) | 75.3 ± 6.3 | 71.9 ± 5.3 | 71.1 ± 6.9 | 71.2 ± 7.7 | 72.9 ± 7.7 | .062 |
| Sex (male %) | 14 (41) | 10 (42) | 17 (40) | 20 (65) | 12 (52) | .20 |
| Years of education | 16.1 ± 2.0 | 16.7 ± 2.9 | 15.8 ± 2.8 | 16.6 ± 2.6 | 15.6 ± 2.7 | .28 |
| APOE ε4 carriers (%) | 11 (32) | 8 (33) | 22 (51) | 14 (45) | 18 (78) | .01 |
| CDR sum‐of‐boxes | 0.06 ± 0.2a , b , c | 0.04 ± 0.1a , b , c | 1.4 ± 1.0a , b , e | 1.7 ± 1.0c , d , e | 4.5 ± 1.2a , b , d , e | <.001 |
| MMSE | 28.9 ± 1.1b , c | 29.1 ± 0.9b , c | 28.3 ± 1.7c | 27.5 ± 1.5c , d , e | 22.3 ± 2.5a , b , d , e | <.001 |
| ADAS‐Cog11 | 5.6 ± 2.5a , b , c | 5.6 ± 2.3b , c | 7.8 ± 3.3b , c , d | 10.9 ± 4.1a , c , d , e | 24.3 ± 7.8a , b , d , e | <.001 |
| RAVLT forgetting (%) | 39.1 ± 24.4b , c | 37.7 ± 22.4b , c | 54.7 ± 29.1c | 67.6 ± 25.9c , d , e | 95.5 ± 10.4a , b , d , e | <.001 |
| Trail making test B | 89 ± 64c | 80 ± 42e | 100 ± 48c | 112 ± 65c | 209 ± 86a , b , d , e | <.001 |
| Amyloid Florbetapir SUVRg | 1.15 ± 0.20c | 1.13 ± 0.18c | 1.21 ± 0.21c | 1.26 ± 0.25c | 1.45 ± 0.18a , b , d , e | <.001 |
| Hippocampal volume (ml)f | 7.6 ± 0.84c | 7.7 ± 1.1e | 7.4 ± 0.9c | 7.2 ± 1.3 | 6.1 ± 1.1a , d , e | <.001 |
| Framewise displacement | 0.15 ± 0.09 | 0.17 ± 0.09 | 0.14 ± 0.07 | 0.13 ± 0.05 | 0.13 ± 0.06 | .66 |
Note: Results are displayed as mean ± SD. A Kruskal–Wallis rank sum test was used for comparison of group differences in continuous variables. Categorical variables were inspected for group differences using a Fisher's exact test with p‐values generated using 2000 Monte Carlo simulations.
Abbreviations: AD, Alzheimer's disease; ADAS‐cog11, 11‐item Alzheimer's disease assessment scale‐cognitive subscale; CDR, clinical dementia rating scale sum‐of‐boxes; CN, cognitively normal; EMCI, early mild cognitive impairment; LMCI, late mild cognitive impairment; MMSE, mini‐mental‐state examination; RAVLT, Rey auditory verbal learning test; SMC, subjective memory complaints; SUVR, standardised uptake value ratio.
Significant compared to EMCI participants.
Significant compared to LMCI participants.
Significant compared to AD patients.
Significant compared to CN participants.
Significant compared to SMC participants.
Fourteen subjects were not considered due to poor FreeSurfer segmentations (SMC = 3, EMCI = 1, LMCI = 7, AD = 3).
Fifteen subjects did not have available amyloid PET imaging (CN = 8, SMC = 2, LMCI = 4, AD = 1).